Physician profile
Amanda D Haugh
NPI 1457597635
$1,443.47
in general payments reported to CMS, 2019-2025
15 companies · $580 in 2025
The $580 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $62.20 · 2022: $48.54 · 2023: $254 · 2024: $498 · 2025: $580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,317 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,317.46 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $317.32 | 2023-2025 | |
| Janssen Biotech, INC. | $282.83 | 2022-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $123.05 | 2023-2025 | Sotyktu |
| Ucb, INC. | $110.90 | 2024-2025 | Bimzelx |
| Amgen INC. | $105.17 | 2022-2025 | Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.17 | 2023-2025 | Spevigo |
| Leo Pharma INC. | $75.13 | 2021-2023 | Adbry |
| Dermavant Sciences, INC. | $72.77 | 2023-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $70.15 | 2024 | |
| Galderma Laboratories, L.P. | $46.94 | 2024-2025 | Nemluvio |
| Lilly USA, LLC | $41.21 | 2023-2024 | Taltz, Olumiant, Ebglyss |
| Organon LLC | $37.99 | 2025 | |
| Pfizer INC. | $32.06 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $20.82 | 2024 | Dupixent |
| Sun Pharmaceutical Industries INC. | $18.96 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Haugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.